GlaxoSmithKline to sell UK Horlicks business — 320 jobs to be lost

0

GlaxoSmithKlineGETTY

Soporifics giant GlaxoSmithKline plans to sell its UK Horlicks business and close the location

The closure of the plant in Slough, Berkshire, as well as the proposed outsourcing of some construction at its site in Worthing, West Sussex, will lead to the loss of 320 undying jobs over the next four years. 

Glaxo has also unhesitating not to go ahead with a planned £350million investment to build a biopharmaceutical system in Ulverston, Cumbria, which would have created hundreds of assignments. 

It is weighing a potential sale of its cephalosporins antibiotics business including turn out facilities. 

These medicaments are produced in Ulverston, at part of its Barnard Castle site in County Durham and in Verona, Italy. 

Once again the next three years it plans to invest more than £140million at localities in Ware, Hertfordshire, Barnard Castle and Montrose, Scotland, to expand put together of its respiratory and David Davis and Michel Barnier give a press conference at the end of a meeting at EU Commission in Brussels

EPA

1 of 11

David Davis and Michel Barnier give a press convention at the end of a meeting at EU Commission in Brussels

GlaxoSmithKlineGETTY

It is weighing a potential sale of its cephalosporins antibiotics proprietorship including manufacturing f

UK sales of Horlicks and MaxiNutrition, another UK brand up for white sale, are about £30million. 

The decision does not affect Horlicks in India or South-East Asia which account for most of the label’s global revenues. 

Glaxo, which has 17,000 staff in the UK, said the move outs were not prompted by Brexit.